08 July 2021>: Clinical Research
Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report
Roger J. Ziętek 1BDF , Zbigniew M. Ziętek 123ACE*DOI: 10.12659/MSM.931597
Med Sci Monit 2021; 27:e931597
Table 2 Baseline and 6-month follow-up International Prostate Symptom Score of patients in the transurethral microwave thermotherapy (TUMT) and pharmacologic (control) groups. P, P1, P2, and P3 indicate statistical significance according to the Z test: P, baseline comparison between TUMT and control group; P1, 6-month follow-up comparison between the TUMT and control groups; P2, only within the TUMT group, baseline vs 6-month follow-up; P3, only within the control group, baseline vs 6-month follow-up.
IPSS scale symptoms | Before | After | P, P1 P2, P3 | ||
---|---|---|---|---|---|
n (%) | n (%) | ||||
TUMT | Control | TUMT | Control | ||
Mild | 98 (12%) | 125 (13%) | 527 (63%) | 485 (47%) | |
Moderate | 612 (73%) | 756 (72%) | 278 (33%) | 458 (44%) | |
Severe | 130 (15%) | 159 (15%) | 35 (4%) | 97 (9%) | |
Total | 840 (100%) | 1040 (100%) | 840 (100%) | 1040 (100%) | |
IPSS – International Prostate Symptom Score; TUMT – transurethral microwave thermotherapy. |